RMD
ResMed| insider trading
Health Care · Heavy selling
Close · Oct 5, 2026
$222.86
-20.0% over 12 months
Share price and insider trades
RMD closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$23.4M
Insiders buying0
Insiders selling5
Valuation, profit and volume
P/E (trailing)21.4Sector median 24.5
Market value$31.34BMedical Instruments & Supplies
Profit margin26.9%Revenue growth +8.6%
Volume vs. 50-day0.7×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 ResMed| insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $23.4M. 31 of 31 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 45 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 10SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $222.44 | $1.1M | +0.2% | — |
| Sep 4SEC | Peter C FarrellDirector | Sell Plan | 970 | $234.73 | $228K | -5.1% | — |
| Aug 11SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $205.69 | $1.0M | +8.3% | — |
| Aug 6SEC | Peter C FarrellDirector | Sell Plan | 8,000 | $225.00 | $1.8M | -1.0% | — |
| Jul 9SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $218.55 | $1.1M | +2.0% | — |
| Jun 9SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $193.96 | $968K | +14.9% | — |
| May 11SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $207.82 | $1.0M | +7.2% | — |
| Apr 9SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $225.50 | $1.1M | -1.2% | — |
| Apr 3SEC | Brett SandercockCFO | Sell Plan | 1,000 | $224.31 | $224K | -0.6% | — |
| Apr 2SEC | Peter C FarrellDirector | Sell Plan | 2,000 | $225.00 | $450K | -1.0% | — |
| Mar 11SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $251.03 | $1.3M | -11.2% | — |
| Mar 5SEC | Peter C FarrellDirector | Sell Plan | 2,000 | $260.22 | $520K | -14.4% | — |
| Mar 3SEC | Brett SandercockCFO | Sell Plan | 1,000 | $254.30 | $254K | -12.4% | — |
| Feb 10SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $273.78 | $1.4M | -18.6% | — |
| Feb 6SEC | Peter C FarrellDirector | Sell Plan | 2,000 | $251.31 | $503K | -11.3% | — |
| Feb 6SEC | Michael J RiderGeneral Counsel | Sell Plan | 50 | $260.00 | $13K | -14.3% | — |
| Feb 3SEC | Brett SandercockCFO | Sell Plan | 1,000 | $257.03 | $257K | -13.3% | — |
| Jan 9SEC | Peter C FarrellDirector | Sell Plan | 2,000 | $248.83 | $498K | -10.4% | — |
| Jan 8SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $248.46 | $1.2M | -10.3% | — |
| Jan 5SEC | Brett SandercockCFO | Sell Plan | 1,000 | $241.75 | $242K | -7.8% | — |
| Jan 5SEC | Michael J RiderGeneral Counsel | Sell Plan | 50 | $241.75 | $12K | -7.8% | — |
| Dec 9SEC | Michael J. FarrellCEO, Chair | Sell Plan | 4,991 | $251.41 | $1.3M | -11.4% | — |
| Dec 4SEC | Peter C FarrellDirector | Sell Plan | 2,000 | $251.47 | $503K | -11.4% | — |
| Dec 2SEC | Brett SandercockCFO | Sell Plan | 1,000 | $244.16 | $244K | -8.7% | — |
| Dec 2SEC | Michael J RiderGeneral Counsel | Sell Plan | 50 | $244.16 | $12K | -8.7% | — |
| Nov 26SEC | Witte Jan DeDirector | Sell Plan | 2,055 | $255.00 | $524K | -12.6% | — |
| Nov 13SEC | Peter C FarrellDirector | Sell Plan | 2,000 | $252.05 | $504K | -11.6% | — |
| Nov 13SEC | Witte Jan DeDirector | Sell Plan | 487 | $250.25 | $122K | -10.9% | — |
| Nov 10SEC | Michael J. FarrellCEO, Chair | Sell Plan | 8,011 | $249.75 | $2.0M | -10.8% | — |
| Nov 4SEC | Brett SandercockCFO | Sell Plan | 3,000 | $247.54 | $743K | -10.0% | — |
| Oct 9SEC | Michael J. FarrellCEO | Sell Plan | 8,009 | $282.85 | $2.3M | -21.2% | — |
Insiders at ResMed|
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Michael J. FarrellCEO, Chair | — | $15.7M | Oct 1, 2026 | — |
| Peter C FarrellDirector | — | $5.0M | Sep 4, 2026 | — |
| Brett SandercockCFO | — | $2.0M | Apr 3, 2026 | — |
| Witte Jan DeDirector | — | $646K | Nov 26, 2025 | — |
| Michael J RiderGeneral Counsel | — | $37K | Oct 1, 2026 | — |
| Aaron BloomerCFO | — | — | Oct 1, 2026 | — |
| Justin LeongChief Product Officer | — | — | Oct 1, 2026 | — |
| Christopher DeloreficeDirector | — | — | Nov 24, 2025 | — |
| Ronald R TaylorDirector | — | — | Nov 24, 2025 | — |
| Carol BurtDirector | — | — | Nov 24, 2025 | — |
| Karen DrexlerDirector | — | — | Nov 24, 2025 | — |
| Harjit GillDirector | — | — | Nov 24, 2025 | — |
| Desney TanDirector | — | — | Nov 24, 2025 | — |
| Nicole Mowad-nassarDirector | — | — | Nov 24, 2025 | — |
| John HernandezDirector | — | — | Nov 24, 2025 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about RMD insiders
Are ResMed| insiders buying RMD stock?
In the past 12 months, 0 insiders reported open-market purchases of RMD worth $0.
Are ResMed| insiders selling RMD stock?
5 insiders reported sales worth $23.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.